Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review / Wrap-Ups
Year in Review
Year in Review
2023
2022
2021
LBCL 2022 Year in Review
NSCLC IO 2022 Midyear Review
AACR & ASCO 2021 – Midyear Review
Dual IO 2021 Year in Review
Year in Review
Novel Transcriptional Signatures Associated with Response to Vidutolimod in Patients with Anti–PD-1-Refractory Melanoma and NSCLC
NSCLC IO 2022 - Midyear Review
Transcriptional signatures of COPII vesicle and Golgi targeting were identified as potential novel response biomarkers to vidutolimod, a first-in-class CpG-A TLR9 agonist, in combination anti–PD-L1-targeted therapy.
Read More ›
Year in Review
Five-Year Survival Outcomes of First-Line Nivolumab plus Ipilimumab versus Chemotherapy in Metastatic NSCLC: CheckMate 227
NSCLC IO 2022 - Midyear Review
The 5-year extended follow-up of CheckMate 227 demonstrated that nivolumab plus ipilimumab continued to provide durable clinical benefit in previously untreated patients with metastatic NSCLC compared with chemotherapy regardless of PD-L1 expression level.
Read More ›
Year in Review
ATM Mutations in NSCLC Define Patients with Distinct Clinicopathologic, Genomic, and Immunophenotypic Characteristics
NSCLC IO 2022 - Midyear Review
Mutations in the
ATM
gene, the most mutated DNA damage and repair gene in cancer, were found to define distinct subsets of patients with NSCLC with unique genomic characteristics, clinicopathologic features, and sensitivity to chemoimmunotherapy.
Read More ›
Year in Review
CTLA-4 Single-Nucleotide Polymorphism Is Associated with High Response to Anti–PD-1/PD-L1 Immunotherapy in Advanced NSCLC
NSCLC IO 2022 - Midyear Review
A noncoding single-nucleotide polymorphism in the CTLA-4 gene was found to be common among responders to anti–PD-1/PD-L1 therapies, which may enhance the clinical effect of PD-1 blockade.
Read More ›
Year in Review
Real-World Effectiveness of Immune Checkpoint Inhibitors with or without Chemotherapy in Metastatic NSCLC
NSCLC IO 2022 - Midyear Review
In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes.
Read More ›
Year in Review
Anti–PD-(L)-1 Monotherapy versus Combination with Chemotherapy in Patients with PD-L1–High Lung Cancer
NSCLC IO 2022 - Midyear Review
Combining anti–PD-(L)-1 with chemotherapy for the treatment of patients with a high PD-L1 expression level did not improve survival compared with anti–PD-(L)-1 monotherapy.
Read More ›
Year in Review
First-Line Anti–PD-(L)1 Therapy with or without Chemotherapy for Advanced PD-L1–High NSCLC: FDA Pooled Analysis
NSCLC IO 2022 - Midyear Review
Treatment of patients with advanced PD-L1–high NSCLC with a combination of immune checkpoint inhibitors and chemotherapy resulted in comparable or better outcomes than immune checkpoint inhibitors alone; however, tolerability was a limiting factor for elderly patients.
Read More ›
Year in Review
Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Resectable NSCLC: CheckMate 816
NSCLC IO 2022 - Midyear Review
Neoadjuvant nivolumab plus platinum-doublet chemotherapy resulted in clinically meaningful improvement in event-free survival and pathologic complete response in patients with resectable NSCLC compared with chemotherapy alone.
Read More ›
Year in Review
Neoadjuvant Durvalumab Alone or Combined with Novel Agents for Resectable, Early-Stage NSCLC: NeoCOAST Trial
NSCLC IO 2022 - Midyear Review
Neoadjuvant treatment of patients with resectable early-stage NSCLC with durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, or the anti-STAT3 antisense oligonucleotide danvatirsen resulted in improved efficacy compared with durvalumab alone.
Read More ›
Year in Review
Canakinumab Combined with First-Line Pembrolizumab and Chemotherapy for Advanced NSCLC: CANOPY-1
NSCLC IO 2022 - Midyear Review
The combination of canakinumab and pembrolizumab plus chemotherapy did not statistically improve efficacy as first-line treatment in patients with advanced NSCLC.
Read More ›
Page 4 of 9
1
2
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us